

University of Groningen

Therapeutic drug monitoring of antimicrobial drugs in neonates. An opinion paper

Touw, D J; van den Anker, J N

Published in:
Therapeutic Drug Monitoring

DOI:
[10.1097/FTD.0000000000000919](https://doi.org/10.1097/FTD.0000000000000919)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Final author's version (accepted by publisher, after peer review)

Publication date:
2022

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Touw, D. J., & van den Anker, J. N. (2022). Therapeutic drug monitoring of antimicrobial drugs in neonates. An opinion paper. *Therapeutic Drug Monitoring*, 44(1), 65-74.
<https://doi.org/10.1097/FTD.0000000000000919>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Corresponding address:

Prof. dr. D.J. Touw, PharmD, PhD, ERT

Department of Clinical Pharmacy and Pharmacology

Internal Postal Code APO50

Hanzeplein 1

9713 GZ Groningen

Netherlands

Telephone: +31 50 3614071

Fax: +31 50 3614087

Mail: d.j.touw@umcg.nl

Conflicts of Interest and Sources of Funding

Prof Touw and Prof van den Anker declare no conflicts of interest, and they received no funding related to this work.

June 23, 2021, revision 1

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited.

The work cannot be used commercially without permission from the journal.

Abstract

Purpose: Neonatal infections are associated with high morbidity and mortality rates. Optimal treatment of these infections requires knowledge of neonatal pharmacology and integration of neonatal developmental pharmacokinetics of antimicrobial drugs in the design of dosing regimens for use with different gestational and postnatal ages. Population pharmacokinetic (PK) and pharmacodynamic (PD) models are used to personalize the use of these drugs in these fragile patients. The final step to further minimize variability in an individual patient is therapeutic drug monitoring (TDM), where the same population PK/PD models are used in concert with optimally drawn blood samples to further fine-tune therapy. The purpose of this manuscript is to describe the present status and future role of model-based precision dosing and TDM of antimicrobial drugs in neonates.

Methods: PubMed was searched for clinical trials or clinical studies of TDM in neonates.

Results: A total of 447 papers were retrieved, of which 19 were concerned with antimicrobial drugs. Two papers (one aminoglycoside and one vancomycin) addressed the effects of TDM in neonates. We found that, in addition to aminoglycosides and vancomycin, TDM also plays a role in beta-lactam antibiotics and antifungal drugs.

Conclusion: There is a growing awareness that, in addition to aminoglycosides and vancomycin, the use of beta-lactam antibiotics, such as amoxicillin and meropenem, and other classes of antimicrobial drugs, such as antifungal drugs, may benefit from

TDM. However, the added value must be shown. New analytical techniques and software development may greatly support these novel developments.

Keywords: TDM, neonate, antibiotic, antifungal, monitoring

ACCEPTED

INTRODUCTION

A standard dose and dosing interval are chosen for most drugs when drug therapy is prescribed to a patient. For example, in a patient with hypertension, a diuretic is initiated at a fixed dose, and after a few weeks, blood pressure is evaluated, and the dose is adjusted based on the obtained effect and side effects.

Dose and effects are investigated during various phases in drug development, and the results of clinical trials and dosing strategies are documented in the registration files. Additionally, a synopsis is published in the Summary of Product Characteristics (SmPC) and product leaflet, which medical professionals use as references in their choice of drug and dose. For many drug classes, this strategy is based on clinical investigations with large groups of patients and usually represents the average effect in the average patient. This average patient can be characterized by the average clearance and volume of distribution of the drug. However, not all patients are average, and not all drugs are harmless if the dose is chosen by the rule of thumb, especially when the clinical effect of the drug cannot be easily monitored, as in the blood pressure-lowering drug example. For these drugs, a personalized dosing method may be more appropriate, and measuring the blood concentration of the drug is one method with which to adjust the dose based on a predetermined target concentration for the drug and a pharmacokinetic (PK)/pharmacodynamic (PD) model to initiate therapy. This method of choosing the correct dose for the initial use by an individual patient could be called “goal-oriented, model-informed, precision dosing,” and it is usually followed by a dose adjustment using predefined target concentrations, which is known as therapeutic drug monitoring (TDM).

Newborn infants are especially vulnerable, and finding the optimal dose to treat these fragile humans is extremely challenging. Neonates are not small adults or children, and the same is true for their PKs. In humans, organs and their functions, such as hepatic metabolic capacity and renal clearance, undergo a steep but variable maturation process after birth. The majority of hepatic phase I and phase II enzymes, which are responsible for drug metabolism, reach maturity after 1 year of age; unfortunately, there is no easy marker to evaluate the developmental stage of the liver.

Neonatal renal function increases after birth. At birth, the glomerular filtration rate is low (10–20 ml/min/1.73 m²) and increases to 30 ml/min/1.73 m² at the age of 2 weeks.¹ Preterm neonates have fewer glomeruli than full-term neonates. This is reflected in the half-life of any renally cleared drug. When designing drug dosage schemes for neonates, developmental considerations must be taken into account. Common descriptors used for maturation include gestational age (GA) and postnatal age (PNA). Other descriptors include body weight (BW) and body surface area (BSA). However, not every neonate has the same speed of organ development, and illness or drug treatment may affect organ function in addition to the already existing intraindividual variability. In this context, establishing the correct renal function in extremely low body weight (ELBW) neonates to tailor individual therapy during the first weeks of life is a special challenge. A classical dogma ignores elevated serum creatinine values because of maternal creatinine transfer to the neonate during pregnancy. However, when the neonate has impaired renal function, part of this elevation is caused by this impairment. Van Donge et al. developed a mathematical model to characterize serum creatinine concentration and creatinine clearance as a function of GA, mode of delivery, and nephrotoxic treatment, such as ibuprofen.² This

model allows the derivation of GA-adjusted reference ranges for ELBW neonates for normative serum creatinine concentrations to optimize therapy. Additionally, this model can quantify drug impact on kidney function after beginning well-known nephrotoxic therapies, such as amikacin and vancomycin.³

In addition to the maturation of liver and kidney function, body composition also changes with age. For example, the body of a preterm neonate consists of 80% total body water, whereas a term neonate has 70%, decreasing to 60% by the toddler age.⁵ This should have consequences for the volume of distribution for highly water-soluble drugs, as is the case for most antibacterial drugs.

Other factors that strongly influence drug PKs in neonates are extracorporeal life support options, such as extracorporeal membrane oxygenation (ECMO) for pulmonary failure and extracorporeal renal support (continuous renal replacement therapy [CRRT]) for kidney failure. ECMO can be life-saving in neonates with cardiac and/or respiratory failure. CRRT is the treatment of choice when the kidneys fail and dialysis is needed. ECMO and CRRT can affect the already altered PKs based on two mechanisms: 1) a rapid increase in the volume of distribution because of the volume of the extracorporeal circuit and the hemodilution that occurs, and 2) sequestration of the drug in different parts of the circuit. By these two mechanisms, a sudden drop in the concentration of the drug can occur, especially when the drug has a small volume of distribution. Additionally, changes in drug clearance can occur because of extracorporeal removal (which is the purpose of CRRT) or the binding of the drug to the circuit. In the latter case, a saturation of the binding sites leads to a reduction in virtual extracorporeal clearance over time.

Therefore, in neonates, the “a priori” predictability of treatment outcome is far less than in the adult population. In these cases, if a relationship exists between the concentration of a drug in a bodily fluid, such as blood, serum, plasma, or saliva, and its clinical effect, the measured concentration can be used as a proxy for the effect and to optimize (personalize) the dose.

Criteria for TDM

Several requirements make the measurement of drug concentration in bodily fluid useful for the optimization of drug therapy.

- 1) There must be a relationship between the concentration of the drug in a bodily fluid (blood, serum, plasma, saliva) and its clinical effect or adverse effects.
- 2) There is no straightforward relationship between the drug dose and its clinical effect or adverse effect.
- 3) There is a narrow therapeutic range, meaning that the margin between efficacy and toxicity is small.
- 4) The inter-patient variability is larger than the therapeutic range.
- 5) The clinical effect is difficult to assess (for example, a drug against cancer or a drug against depression may take weeks to months to show an effect).
- 6) The results need to be properly interpreted, preferably using state-of-the-art software tools, such as Bayesian optimization and population PK models, in concert with pharmacodynamically determined target values and optimal blood sampling.

However, there are situations where TDM is not possible.

7) There is no assay for the drug available.

8) The dose cannot easily be adjusted.

Currently, point 7 is less of an issue. In the past, analytical possibilities relied on the availability of commercial assays, such as ligand-binding assays. In special cases, hospitals also use high-performance liquid chromatographic or gas-chromatographic methods to develop their in-house assays, but this is usually only possible in academic and top-clinical hospitals. These classical chromatographic methods lacked sensitivity for the low concentrations of many drugs, and time-consuming pre-analytical techniques, such as solid-phase or liquid-liquid extraction and the concentration of the resulting organic layer, were necessary before chromatographic separation and quantification could take place. Consequently, larger sample volumes (usually 0.5–1 ml serum or plasma) are usually required to reach the necessary lower limit of quantitation. This is a serious drawback for the widespread introduction of TDM in neonatal care. Currently, liquid chromatography with tandem mass spectrometry (LC-MSMS) has become an affordable technology that is well-established in many hospitals, and it can be used to develop assays for drugs if no commercially available assay exists.⁴ Major points in favor of LC-MSMS are the small sample volumes necessary (usually only 10 μ L of serum or plasma) and that simple, fast sample clean-ups, such as simple protein precipitation with a solution containing an internal standard before analysis, can be performed. Additionally, the wide availability of stable isotopes of the analytes of interest makes chromatographic separation and sample pre-treatment less important because these stable isotopes correct for matrix effects.

For primarily parenterally administered drugs, such as antimicrobials, point 8 is even less relevant.

Antimicrobial Drugs

Antimicrobial drugs are among the most frequently used drugs in neonates. On average, 36.7% of the hospitalized children receive antimicrobial drugs.⁵ This figure ranges from 12.3% in a general neonatal ward to 61.3% in a pediatric intensive care unit.⁵ Prescribing antimicrobial drugs in neonates is more complex than in adults because of the aforementioned aspects of maturation and extracorporeal life support options, making it a challenge. Additionally, most antibiotics have not been well investigated in pediatric patients, especially neonates. Because of ethical considerations, new drugs are usually investigated in adults, and after licensing, neonatal dosing regimens are derived from studies in adults; therefore, no formal SmPC dose advice exists, which means that their use is usually off-label. Although techniques, such as allometric scaling and recent models that capture developmental changes in clearance, are used to best predict age-appropriate dosing schemes in neonates,^{6,7} dosing remains an estimation. For some drugs, real-life neonatal PK studies have been published, but these data are usually collected in left-over material during regular off-label use and not in formal PK studies.

Serious infections, such as sepsis, are associated with high morbidity and mortality. In 2002, critical care and infectious disease specialists issued a plan to develop guidelines for treating severe sepsis and septic shock.⁸ Every hour of delay in starting the appropriate treatment increases mortality by 10%, and one of the cornerstones of

this “surviving sepsis campaign” was early treatment with an appropriate dose of the right antibacterial drug.⁹

As explained above, newborn neonates have a higher extracellular volume than children and adults.¹⁰ Most antibiotics are hydrophilic; thus, they are highly water-soluble and easily distributed into extracellular compartments, leading to a higher volume of distribution when expressed in liters per kg BW in neonates than in children and adults. This implies that to obtain adequate antimicrobial drug levels quickly, a higher loading dose per kg BW must be administered. Immature clearance results in a lower or less frequent maintenance dose. For some drugs, special neonatal nomograms have been developed based on the dosing guidelines.^{11,12} However, nomograms are still simplifications, and the remaining high intraindividual variability resulting in poor target attainment makes a strong case for TDM.¹³

The goal of this opinion paper is to describe the current state of the art of TDM using current analytical techniques and software support to perform optimal model-informed precision dosing of antimicrobial drugs in this special group of patients.

METHODS

Literature Search

To obtain information from published original evidence for TDM practices of antimicrobial drugs and outcomes in neonates, PubMed was searched using the following terms: (“Therapeutic” AND “Drug” AND “Monitoring”) OR “TDM”]

AND [“neonate” OR “neonates” AND “Clinical Trial” OR “Clinical Study”]). Then, the retrieved papers were manually selected for antimicrobial drugs.

Additionally, the literature was searched for background information on the retrieved classes of drugs. This background information comprised PK/PD background and relevant population PK studies.

RESULTS

Literature Search

A total of 447 papers were retrieved. After reviewing the titles and abstracts, 19 articles that discussed antimicrobial drugs were selected. Of these 19 papers, seven discussed aminoglycosides (gentamicin or netilmicin), five papers discussed beta-lactam antibiotics (amoxicillin, flucloxacillin, piperacillin, meropenem, and ceftazidime), three discussed glycopeptide drugs (vancomycin and teicoplanin), two discussed fluoroquinolones (ciprofloxacin), one paper discussed MRSA drugs in general, and one discussed antimycotic drugs (amphotericin B, caspofungin). After reading the papers, only two papers used TDM to adjust doses and evaluated the impact of TDM on future drug concentrations.^{14,15}

DISCUSSION, GAP ANALYSIS, AND OUTLOOK

Tools for TDM

TDM measures drug concentration during the steady-state and adjusts the dose accordingly by applying linear PKs. In stable patients, steady-state concentrations will be reached after four half-lives. This approach can be applied where applicable.

However, in neonates, with immature clearance resulting in longer half-lives that are difficult to predict, doctors must wait longer than adults before a steady-state is reached. Additionally, neonates are seldom stable; thus, PKs may change from day to day. The Bayesian population PK modeling software is a valuable tool for TDM in neonates. Software packages for Bayesian TDM first appeared 30 years ago.

However, they are operated via the command line and are generally too complicated for widespread use. Publications largely reflect local expertise, and there is currently substantial geographical variability in the use of Bayesian TDM software. However, software technology has greatly improved and became more user-friendly, making Bayesian TDM increasingly feasible for widespread implementation. In 2013, the first overview of available software was published, and new tools have been developed since that review.¹⁶⁻¹⁸ Examples of widely used software for TDM with some

applications used in the pediatric population are MWPharm® (e.g., flucloxacillin¹⁹), BestDose® (e.g., teicoplanin²⁰), InsightRx® (vancomycin²¹), NextDose® (busulfan²²), and Monolix® (e.g., vancomycin²³). The reader is referred to the available literature because this field is developing quickly, and this list will soon be outdated. The core of the available software is a population PK model and a calculation tool, usually a Bayesian estimator. The population PK model is based on the PK parameter values of many individuals with the same characteristics. This will

result in mean parameter values and their associated standard deviations for the entire population from which these parameters are derived. Additionally, confounders that can be used to further individualize these PK variables can be identified. This information can be obtained from the literature or from doctors' patients who have already been followed by TDM. The Bayesian approach allows adjustment of the dose in the early phase when the steady-state has not yet been reached. Early adaptation of the dose allows the achievement of therapeutic goals earlier with higher precision and a better chance for therapeutic success. For example, Van Lent-Evers et al. and Bartal et al. demonstrated the success of this strategy in adults.^{24,25} An essential aspect for an accurate estimation of actual individual PK parameters and prediction of the correct dose is the optimization of the sampling process. Figure 1 shows that a blood sample drawn immediately after the intravenous administration of a drug provides much information on the volume of distribution (V_d). However, no information on the elimination rate (k_{el}) and a sample drawn 1.44 times the half-life after the end of administration (given as intravenous dose) provides the most information on the k_{el} of the same drug.²⁶ When an intravenous drug treatment is started, the time for the maximum drug concentration is easily established, but for the time point that provides the most information on elimination, an estimation based on the average half-life in this population still needs to be made.

INSERT FIGURE 1 HERE

To avoid unnecessary blood sampling of neonates, sparse sampling is recommended. Formally, for every PK parameter that is part of a PK model, a separate blood sample needs to be drawn. However, Bayesian software allows prior knowledge regarding the PK parameters in other but similar patients, thereby reducing the number of samples

needed to calculate reliable dose adjustments. Furthermore, the principle of D-optimality has been described by Drusano et al. and Sallas,^{27,28} and software exists that can calculate optimal sampling times for a given PK model and a reasonable number of samples, such as the design module of the ADAPT II package of the programs of D'Argenio and Schumitzky.²⁹ Using optimally drawn samples in combination with Bayesian PK software allows for the attainment of therapeutic targets in a timely manner with a minimal burden on the patient.

Aminoglycosides

The classic example of TDM in neonates is that of aminoglycosides.

Aminoglycosides, such as gentamicin, netilmicin, tobramycin, and amikacin, are among the most widely used antimicrobial drugs in neonates.⁵

The emergence of multi-resistant bacteria and the impression that the decline in susceptibility to aminoglycoside antibiotics is less steep than expected has renewed interest in these highly effective and potentially toxic antibiotics. The basic chemical structure required for high potency and a broad spectrum of the antimicrobial activity of aminoglycosides is that of one or several aminated sugars joined by glycosidic linkages to a dibasic cyclitol (2-deoxystreptamine, in most clinically used aminoglycosides).³⁰ Aminoglycosides act primarily by impairing bacterial protein synthesis by binding to prokaryotic ribosomes.³⁰ Passage of these highly polar molecules across the outer membrane of gram-negative bacteria is a self-promoted uptake process involving drug-induced disruption of the lipopolysaccharide outer membrane. After penetration through the inner membrane, they bind to the 30S

subunit of ribosomes in the cytosol.³⁰ This leads to proofreading perturbation of nascent proteins and impaired quality control of the bacterial protein production process with more aberrant proteins inserted into the cell membrane. These actions lead to instability of the outer cell membranes, increased penetration of aminoglycosides, and ultimately cell death.³⁰ Through the disruption of cell membranes, aminoglycosides also potentiate the efficacy of beta-lactam antibiotics that also affect cell membrane structure. Although all clinically used aminoglycosides are inhibitors of prokaryotic protein synthesis at commonly accepted therapeutic concentrations, at higher concentrations, they may also affect protein synthesis of mammalian cells, leading to clinically relevant toxicity, including nephrotoxicity, ototoxicity, and vestibulotoxicity.³¹ However, in mammalian cells, it has been demonstrated that aminoglycoside uptake is saturable,³² thereby allowing comparatively high concentrations with relatively low toxicity.

Because of their efficacy, aminoglycosides continue to play a valuable role in treating infections caused by aerobic gram-negative bacteria. However, for optimal use of these agents, it is necessary to understand the PK/PD indices, which are determinants of their therapeutic efficacy and toxicity, to perform rational dose adaptations.

Aminoglycosides are highly effective antimicrobial drugs that display concentration-dependent bactericidal activity.^{33,34} The determinants of efficacy are related to the sensitivity of the infecting microorganism but also to their PK profile. The antibacterial drug concentration (in vitro) where no growth or killing occurs is called the minimal inhibitory concentration (MIC). When aminoglycoside-susceptible microorganisms are exposed to increasing concentrations of an aminoglycoside in terms of fold-MIC, their number (expressed as colony-forming units (CFU) per unit of

mass or volume decreases (Figure 2). Another mechanism of relevance for the dosing regimen is related to the interplay between aminoglycosides and microorganisms. This is a post-antibiotic or post-MIC effect. Aminoglycosides exhibit prolonged bacterial killing after clinical concentrations have dropped below the MIC value for the microorganism.³⁵

INSERT FIGURE 2 HERE

In addition to in vitro and animal studies, clinical studies have shown that higher peak blood concentrations of aminoglycosides are associated with increased survival and better therapeutic responses in patients with gram-negative infections.³⁶ Given these associations, a relationship between the clinical response to aminoglycoside therapy and the ratio of the maximum concentration in the blood of the patient and the MIC for the pathogen has been demonstrated,³⁴ and a ratio of at least eight needs to be achieved. It has also been demonstrated that the (C_{max}/MIC) ratio is related to clinical efficacy; however, the area under the curve (AUC) divided by the MIC (AUC/MIC) ratio can be used.³⁷ These relationships have led to the concept of administering higher doses for longer dosing intervals. This “once-daily-dosing” concept was first validated and is currently widely accepted in adults,³⁸ but has also been implemented in children and neonates.^{39–42}

In neonates, treatment with an aminoglycoside is usually started with a standard dose based on BW and is “a priori” adjusted for estimated renal function. Typical values for the volume of distribution of the aminoglycosides are 0.41–0.53 L/kg.^{13,43}

The target drug concentrations are based on efficacy and toxicity. Based on the principles described above, target concentrations for aminoglycosides must be defined

before TDM can be applied. It is clear that there no general therapeutic range exists. Every patient has their optimal target concentration, based on the susceptibility of the microorganism, co-administered antibiotics, immune status of the patient, and co-administration of other nephrotoxic or ototoxic drugs. However, when therapy is initiated, these variables may not be known, and the first dose is usually based on population values for the volume of distribution and expected susceptibility of the targeted microorganism. As a result, aminoglycoside target peak concentrations may differ among countries, but widely adapted peak concentrations for gentamicin and tobramycin in neonatology range 8–12 mg/L with a pre-dose trough concentration of <1 mg/L.¹³ For amikacin, because of its lower intrinsic antibacterial and toxic effects, target peak levels are >30 mg/L with pre-dose trough levels of 2–5 mg/L.⁴¹ Together with an average volume of distribution of 0.4–0.5 L/kg, over time this has resulted in initial doses of 5 mg/kg bodyweight for gentamicin,^{13,44} 4 mg/kg for tobramycin,¹³ and 15–20 mg/kg for amikacin.⁴¹

However, when a gentamicin dose of 5 mg/kg was administered to a population of neonates, a wide variety of peak concentrations was obtained (Figure 3).¹³ Further, from this study, it was clear that the stage of maturation (GA) of the neonate played a role. The outcomes of TDM studies largely depend on defined target concentrations. If a wide range of peak concentrations is accepted, the need for TDM is low because most of the concentrations will be in the defined range. However, if narrow target concentrations are defined, there needs to be a substantial effort (TDM) to optimize the therapy. For example, in Figure 3, if the desired peak concentration should be 8–12 mg/L, approximately 80% of the measured peak concentrations fulfill this criterion, and if the required peak concentration is supposed to be >5 mg/L, 99% of

the measured peak concentrations fulfill this criterion. Therefore, using the PK/PD principles described above and considering the risk of toxicity, narrow peak concentrations are currently advocated. This high interindividual variability underlines the need for early intervention after initiating treatment.

INSERT FIGURE 3 HERE

Aminoglycosides are eliminated unchanged up to 90% by the kidneys, and only a small portion is metabolized through the liver. Aminoglycosides are filtered by the glomerulus, and there is no evidence of tubular reabsorption or active secretion. Therefore, clearance parallels renal function expressed as (estimated) glomerular filtration rate ((e)GFR), except in patients with terminal kidney disease, where the liver plays the most important role in clearance.

Assessment of renal function using plasma creatinine concentration within the first days of life is difficult in clinical practice, as discussed above. Plasma creatinine concentration during this period in the neonate partly reflects the maternal creatinine concentration and is widely neglected. Developmental changes in renal function are reflected in the half-life of any renally cleared drug. Gentamicin, for example, has a half-life of 12–14 h at a GA of <25 weeks, compared to 6–7 h at a GA of >32 weeks, whereas clearance increases to 0.41–1.05 mL/kg/min.⁴⁵ After birth, irrespective of GA, clearance rapidly increases, and half-life decreases.⁴⁵ Based on these prenatal- and postnatal-maturation-dependent findings regarding the volume of distribution and renal drug clearance, dosing schemes have been developed for drugs with known target peaks and trough concentrations, see Table 1 for an example using gentamicin.⁴⁶

INSERT TABLE 1 HERE

The high interindividual and intraindividual variability stresses the need to optimize the dose immediately after the first dose. This requires a good logistic process for drawing a blood sample, measuring the concentration, and calculating the optimal dose. Taking the first sample immediately after the first dose and the second sample not as a pre-dose trough concentration but 10–12 h after the first dose facilitates the correct dose and dose interval calculation before the second dose is administered. For optimal dose prediction, Bayesian PK software equipped with the appropriate PK models is required. Successful predictive performance of this early sampling approach has been demonstrated in neonates by Isemann et al.¹⁴ Currently, the TDM of aminoglycosides in neonates is the standard of practice. A very limited number of studies have been published that have shown beneficial results in neonates; however, it is unethical to perform randomized controlled studies because the PK/PD background and existing evidence in adults are overwhelming.

Vancomycin

Vancomycin is a glycopeptide antibacterial drug that binds to the cell wall precursor d-alanyl-d-alanine, which is crucial for peptidoglycan crosslinking. Disruption leads to bacterial killing in most gram-positive species. The most recent guideline of the Infectious Diseases Society of America (IDSA), issued in 2020, advises to guide vancomycin dosing based on the AUC with a target 24 h AUC of 400–600 mg · h/L for pediatric patients.⁴⁷ Because the *in vitro* vancomycin PK/PD index is an AUC/MIC ratio of 400, this target can only be used for microorganisms with a MIC

of up to 1 mg/L. However, a recent Chinese study demonstrated that a lower 24 h AUC target of 240–480 mg · h/L is likely more effective for neonates than adults.¹³ In contrast to aminoglycosides, trough concentrations need to be >10–15 mg/L to prevent under-treatment because of the absence of a post-MIC effect.

Because vancomycin PKs are determined by the volume of distribution and renal clearance,⁴⁸ neonatal dose recommendations are (similar to aminoglycosides) based on GA and PNA, as shown in Table 2.⁴⁹

INSERT TABLE 2 HERE

In clinical practice, most clinicians use the pre-dose trough concentration of vancomycin as a surrogate for the 24 h AUC. Although a simple approach, trough concentration poorly predicts the AUC.^{47,50} However, early high trough concentrations (>20 mg/L) and day one exposure are predictive of clinical outcomes,⁴⁷ which necessitates early (day 1) sampling together with the use of Bayesian software-supported model-informed precision dosing to individualize therapy.^{51,52}

In adults, continuous infusion of vancomycin is becoming the standard of practice, especially in ICU units. In the pediatric population, continuous infusion of vancomycin has been studied.¹⁵ The advantages of continuous infusion are better target attainment and less difficulty in drug monitoring with easier interpretation of drug levels. Additionally, AUC targets are reached with fewer dose adjustments and with lower daily doses.¹⁵

In this study, there was no difference in toxicity between the groups; however, continuous infusion tended to be less toxic in adults.⁵³ Currently, the TDM of

vancomycin in neonates is the standard of practice. Although limited studies have been published that have shown a benefit of TDM in neonates, it is unethical to perform randomized controlled studies because the PK/PD background and existing evidence in adults in favor of TDM are overwhelming. Additionally, Bayesian software with appropriate PK models should be used to individualize and optimize therapy.⁵⁴ As is the case in adults, vancomycin treatment is slowly shifting towards continuous infusion, which facilitates interpretation of drug levels and adjustment of the dose according to the measured concentration and reduces the dose needed to attain the AUC target, which could reduce toxicity.

Beta-lactam Antibiotics

Beta-lactam antibiotics act through the direct disruption of the cellular wall of the pathogen. Peptidoglycan is a heteropolymer and an essential component that provides essential mechanical stability to the bacterial cell wall. During bacterial growth and division, peptidoglycan is produced in several stages, and the final stage is the crosslinking of single peptide chains. Crosslinking is accomplished by a transpeptidase enzyme outside of the cell membrane. Because of their structural similarity, beta-lactam antibiotics can inhibit transpeptidase, thereby halting crosslinking and disrupting bacterial cell wall structure and stability. This leads to the lysis of the dividing bacterium. Beta-lactam antibiotics, often used in neonates, are beta-lactamase-sensitive and resistant penicillins, 1st to 4th generation cephalosporins, and carbapenems.⁵ Fifty to 60% of the prescribed antimicrobial drugs in neonates are beta-lactams.⁵ Beta-lactam antibiotics are mainly eliminated through glomerular filtration and active secretion (for example, flucloxacillin, piperacillin, cephadrine,

and cefaclor), although some are metabolized in the liver (e.g., flucloxacillin). SmPC dosing schemes aim to maintain the plasma concentration of the free (not plasma protein-bound) drug for at least 40–50% of the time above the MIC of the suspected microorganism (fTime>MIC). However, adult studies have demonstrated that in cases of severe infection, the outcome is better if fTime>MIC for 100% of the dosing interval, thereby advocating for either very high intermittent dosing, prolonged infusion, or better administration of beta-lactam antibiotics in the form of a continuous infusion.⁵⁵ Because of the high safety level of beta-lactam antibiotics, TDM is rarely performed in clinical practice. However, the question is whether this is justified. Severely ill patients often display different PKs with a much higher volume of distribution and augmented renal clearance (>130 mL/min/1.73 m²), leading to the risk of undergoing treatment,⁵⁵ and there is evidence that pediatric dosing strategies for beta-lactam antibiotics are not better.¹⁹ The added value of TDM is currently under investigation in critically ill adults.⁵⁶ However, some beta-lactam antibiotics can cause neurotoxicity when serum concentrations are too high,⁵⁷ limiting irrationally high doses. A common barrier to TDM of beta-lactam antibiotics is because LC-MSMS methods exist for the rapid analysis of these drugs.⁴ Although well documented in adults, PK and PD of these antibiotics are poorly explored in critically ill neonates, the sparsity of studies suggests that current dosing is frequently inadequate.^{59–61} Therefore, there is an urgent need to characterize a population PK of commonly used beta-lactams in neonates associated with target attainment to develop evidence-based dosing schemes and TDM practices. Recently, population PK models for the penicillins, amoxicillin, piperacillin, and azlocillin, and the cephalosporin cefthiamidone have been developed and used to calculate target attainment with present SmPC and local dosing schemes.^{62–65} Meropenem is the most widely used

carbapenem in neonates.⁵ Pharmacokinetics have been studied in neonates and young children.⁶⁶⁻⁶⁹ Compared with adults, total body clearance of meropenem in neonates was comparable; however, the volume of distribution was considerably greater in neonates (38.6 L/70 kg BW versus 22.4 L/70 kg BW).^{66,70} In agreement with aminoglycosides, this implies that higher loading doses per kg BW are needed in neonates for an adequate plasma concentration. These and other population PK models can be used to design rational dosing schemes for neonates and, in combination with optimal sampling schemes for TDM purposes, to further individualize these therapies according to the needs of individual patients.

Antifungal Drugs

In neonates, the incidence of fungal infections is increasing. Any fungal infection in the neonate can be life-threatening, and a delay in diagnosis often results in significant morbidity or mortality. Currently, amphotericin B is the standard therapy for *Candida* infections. However, amphotericin suffers from significant toxicity, and new antifungal agents, such as echinocandins (e.g., caspofungin) or the new generation azole derivatives, have been developed over the past decade. Some clinical experience has been reported regarding the treatment of neonates with *Candida* and *Aspergillus* infections.^{71,72} A prospective study by Mohammed et al. investigated the efficacy, safety, and tolerability of caspofungin versus amphotericin B in neonates.⁷¹ Although retrieved in our search, patients were treated with standard doses of both drugs, and no serum drug concentrations were measured to adjust the therapy.

Based on clinical experience, azoles have also been used in pediatric antifungal infections. Azole antifungal drugs inhibit fungal cytochrome P450 activity, decrease ergosterol synthesis, and inhibit cell membrane formation. The antifungal drug voriconazole is a broad-spectrum triazole agent that is currently the preferred treatment for invasive aspergillosis in adults and children ≥ 2 years of age. Voriconazole is also effective in the treatment of *Candida* infections. As with many other drugs, voriconazole is currently used off-label in children < 2 years of age and neonates. Voriconazole exposure has been associated with treatment outcomes in adults, with a suggested cutoff point for voriconazole trough plasma concentrations of 1–5.5 mg/L.⁷³ In pediatric patients, an exposure-response relationship was established, in which a voriconazole trough concentration > 1 mg/L was associated with improved outcomes.⁷⁴ However, hepatic toxicity can occur at a trough level of > 6 mg/L.⁷⁵ Voriconazole is a substrate for CYP2C9, 2C129, and 3A4, displaying developmental and genetic-based variance in PKs. Moreover, voriconazole displays dose-dependent PKs because of the saturation of its metabolism and further inflammation-associated downregulation of metabolic enzymes.⁷⁶ Based on the relationship between voriconazole exposure and efficacy and the resulting high inter- and time-dependent intra-patient variability, the importance of voriconazole TDM has been acknowledged.⁷² Although TDM-based dose adjustments are widely performed in adults to optimize plasma concentrations, it remains unclear whether this method of dose adaptation is used in pediatric patients. Few studies have been performed on pediatric patients, and no studies have been conducted on neonatal patients.⁷⁷ However, in light of the PK difficulties described above and if no other treatment options are available, optimal use of voriconazole guided by TDM is warranted.⁷⁷

Fluconazole is another widely used antifungal drug for neonatal candidiasis. From data extrapolated from adult studies, fluconazole is excreted primarily partly unchanged in the urine and has excellent penetration into the cerebral spinal fluid. For candidiasis treatment, the target area under the concentration curve for 24 h (AUC₂₄) is ≥ 400 mg · h/L, and with a MIC breakpoint ≤ 8 mg/L, a ratio of AUC₂₄/MIC > 50 mg · hr/L is associated with clinical efficacy in adult patients.^{78,79} In contrast to adult data, PK studies in infants have demonstrated that higher doses of 12 mg/kg/d are required to reach these target concentrations.⁸⁰ Although fluconazole is generally considered safe in pediatric patients,⁸¹ neurotoxicity has been reported at high concentrations.⁸² The combination of a higher dose for comparable exposure and the risk of neurotoxicity makes fluconazole a candidate for TDM.

CONCLUSION

The goal of TDM is to integrate concentration measurements of a drug as part of clinical decision-making. Aminoglycosides and vancomycin are well-known fields of TDM. However, the upcoming fields for TDM are beta-lactam antibiotics and antifungal drugs, especially voriconazole, because of their poorly predictable PKs. Neonates display wide interindividual variability in PKs and intra-individual variability because of organ maturation immediately after birth and extracorporeal life support factors. This variability hinders good correlations between the dose and concentration of a drug with a serious risk of underdosing, which provides a strong case for goal-oriented, model-informed precision dosing. This is further optimized by measuring one or more drug concentrations that are interpreted using Bayesian PK optimization software. New analytical techniques, such as LC-MSMS, have closed the

gap between the need for measurements of serum or plasma drug concentrations and the availability of such assays. Personalized precision dosing cannot be performed without Bayesian software or proper population PK models with confounder identification. Currently, tools available for model development need to be widely adapted to develop validated dosing regimens. Additionally, these models can be used with early optimal TDM sampling and Bayesian forecasting to tailor pharmacotherapy to meet the individual needs of neonates.

ACCEPTED

REFERENCES

1. Salem F, Johnson TN, Hodgkinson ABJ, Ogungbenro K, Rostami-Hodjegan A. Does “birth” as an event impact maturation trajectory of renal clearance via glomerular filtration? Reexamining data in preterm and full-term neonates by avoiding the creatinine bias. *J Clin Pharmacol.* 2021;61(2):159–171. doi:10.1002/jcph.1725
2. van Donge T, Allegaert K, Gotta V, et al. Characterizing dynamics of serum creatinine and creatinine clearance in extremely low birth weight neonates during the first 6 weeks of life. *Pediatr Nephrol.* 2021;36(3):649–659. doi:10.1007/s00467-020-04749-3
3. van Donge T, Smits A, van den Anker J, Allegaert K. Amikacin or vancomycin exposure alters the postnatal serum creatinine dynamics in extreme low birth weight neonates. *Int J Environ Res Public Health.* 2021;18(2):1–11. doi:10.3390/ijerph18020662
4. Veringa A, Sturkenboom MGG, Dekkers BGJ, et al. LC-MS/MS for therapeutic drug monitoring of anti-infective drugs. *Trends Anal Chem.* 2016;84:34–40. doi:10.1016/j.trac.2015.11.026
5. Versporten A, Bielicki J, Drapier N, et al. The worldwide antibiotic resistance and prescribing in european children (ARPEC) point prevalence survey: Developing hospital-quality indicators of antibiotic prescribing for children. *J Antimicrob Chemother.* 2016;71(4):1106–1117. doi:10.1093/jac/dkv418

6. Mizuno T, Gist KM, Gao Z, et al. Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infants with Acute Kidney Injury Following Cardiac Surgery. *Clin Pharmacokinet*. 2019;58(6):793–803. doi:10.1007/s40262-018-0729-3
7. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. *Clin Pharmacokinet*. 2006;45(9):931–956. doi:10.2165/00003088-200645090-00005
8. Slade E, Tamber PS, Vincent JL. The surviving sepsis campaign: Raising awareness to reduce mortality. *Crit Care*. 2003;7(1):1–2. doi:10.1186/cc1876
9. Shapiro NI, Howell M, Talmor D. A blueprint for a sepsis protocol. *Acad Emerg Med*. 2005;12(4):352–359. doi:10.1197/j.aem.2004.11.017
10. de Rose DU, Cairoli S, Dionisi M, et al. Therapeutic drug monitoring is a feasible tool to personalize drug administration in neonates using new techniques: An overview on the pharmacokinetics and pharmacodynamics in neonatal age. *Int J Mol Sci*. 2020;21(16):1–25. doi:10.3390/ijms21165898
11. Murphy JE, Roether AM. Two nomograms for determining extended-dosing intervals for gentamicin in neonates. *Am J Health-Syst Pharm*. 2008;65(7):624–630. doi:10.2146/ajhp070314
12. Pokorná P, Šíma M, Černá O, Allegaert K, Tibboel D SO. Actual body weight-based vancomycin dosing in neonates. *J Chemother*. 2019;31(6):307–312. doi:10.1080/1120009X.2019.1599574

13. Hartman SJF, Orriëns LB, Zwaag SM, Poel T, de Hoop M, de Wildt SN. External validation of model-based dosing guidelines for vancomycin, gentamicin, and tobramycin in critically ill neonates and children: A pragmatic two-center study. *Paediatr Drugs*. 2020;22(4):433–444. doi:10.1007/s40272-020-00400-8
14. Isemann B, Kotagal U, Mashni S, Luckhaupt E, Johnson C. Optimal gentamicin therapy in preterm neonates includes loading doses and early monitoring. *Ther Drug Monit*. 1996;18(5):549–555. doi:10.1097/00007691-199610000-00005
15. Gwee A, Cranswick N, McMullan B, et al. Continuous versus intermittent vancomycin infusions in infants: A randomized controlled trial. *Pediatrics*. 2019;143(2). doi:10.1542/peds.2018–2179
16. Kantasiripitak W, van Daele R, Gijsen M, Ferrante M, Spriet I, Dreesen E. Software Tools for Model-Informed Precision Dosing: How Well Do They Satisfy the Needs? *Front. Pharmacol*. 2020;11(May). doi:10.3389/fphar.2020.00620
17. Fuchs A, Csajka C, Thoma Y, Buclin T, Widmer N. Benchmarking therapeutic drug monitoring software: A review of available computer tools. *Clin. Pharmacokinet*. 2013;52(1):9–22. doi:10.1007/s40262-012-0020-y
18. Drennan P, Doogue M, van Hal SJ, Chin P. Bayesian therapeutic drug monitoring software: past, present and future. *Int J Pharmacokinet*. 2018;3(4):109–114. doi:10.4155/ipk-2018-0005

19. Pullen J, de Rosario L, Stolk LML, Degraeuwe PLJ, van Tiel FH, Zimmerman LJI. Population pharmacokinetics and dosing of flucloxacillin in preterm and term neonates. *Ther Drug Monit.* 2006;28(3):351–358.
doi:10.1097/01.ftd.0000211831.96102.91
20. Ramos-Martín V, Neely MN, Padmore K, et al. Tools for the individualized therapy of teicoplanin for neonates and children. *Antimicrob Agents Chemother.* 2017;61(10). doi:10.1128/AAC.00707-17
21. Frymoyer A, Schwenk HT, Zorn Y, et al. Model-informed precision dosing of vancomycin in hospitalized children: Implementation and adoption at an academic children’s hospital. *Front Pharmacol.* 2020;11.
doi:10.3389/fphar.2020.00551
22. Lawson R, Paterson L, Fraser CJ, Hennig S. Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation. *Cancer Chemother Pharmacol.* 2021;(0123456789).
doi:10.1007/s00280-021-04288-0
23. Mulubwa M, Griesel HA, Mugabo P, Dippenaar R, van Wyk L. Assessment of vancomycin pharmacokinetics and dose regimen optimisation in preterm neonates. *Drugs R D.* 2020;20:105–113. doi:10.1007/s40268-020-00302-7
24. Bartal C, Danon A, Schlaeffer F, et al. Pharmacokinetic dosing of aminoglycosides: A controlled trial. *Am J Med.* 2003;114(3):194–198.
doi:10.1016/S0002-9343(02)01476-6

25. van Lent-Evers NA, Mathôt RA, Geus WP, van Hout BA VA. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. *Ther Drug Monit.* 1999;21(1):63–73. doi:10.1097/00007691-199902000-00010
26. Jelliffe RW, Iglesias T, Hurst AK, Foo KA, Rodriguez J. Individualising gentamicin dosage regimens. A comparative review of selected models, data fitting methods and monitoring strategies. *Clin Pharmacokinet.* 1991;21(6):461–478. doi:10.2165/00003088-199121060-00006
27. Drusano GL, Forrest A, Snyder MJ, Reed MD, Blumer JL. An evaluation of optimal sampling strategy and adaptive study design. *Clin Pharmacol Ther.* 1988;44(2):232–238. doi:10.1038/clpt.1988.142
28. Sallas WM. Development of limited sampling strategies for characteristics of a pharmacokinetic profile. *J Pharmacokinet Pharmacodyn.* 1995;23(5):515–529. doi:10.1007/BF02353472
29. Tam VH, Preston SL, Drusano GL. Optimal sampling schedule design for populations of patients. *Antimicrob Agents Chemother.* 2003;47(9):2888–2891. doi:10.1128/AAC.47.9.2888-2891.2003
30. Krause KM, Serio AW, Kane TR, Connolly LE. Aminoglycosides: An overview. *Cold Spring Harb Perspect Med.* 2016;6(6):1–18. doi:10.1101/cshperspect.a027029

31. Jospe-Kaufman M, Siomin L, Fridman M. The relationship between the structure and toxicity of aminoglycoside antibiotics. *Bioorg Med Chem Lett*. 2020;30(13). doi:10.1016/j.bmcl.2020.127218
32. de Broe ME, Giuliano RA, Verpooten GA. Choice of drug and dosage regimen: Two important risk factors for aminoglycoside nephrotoxicity. *Am J Med*. 1986;80(6 SUPPL. 2):115–118. doi:10.1016/0002-9343(86)90488-2
33. Aronson JK, Reynolds DJM. ABC of monitoring drug therapy: Aminoglycoside antibiotics. *Br Med J*. 1992;305(6866):1421–1424. doi:10.1136/bmj.305.6866.1421
34. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. *Int J Infect Dis*. 1987;155(1):93–99. doi:10.1093/infdis/155.1.93
35. Craig WA. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. *J Antimicrob Chemother*. 1993;31:149–158. doi:10.1093/jac/31.suppl_D.149
36. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. *J Infect Dis*. 1984;149(3):443–448. doi:10.1093/infdis/149.3.443
37. Mouton JW, Jacobs N, Tiddens H, Horrevorts AM. Pharmacodynamics of tobramycin in patients with cystic fibrosis. *Diagn Microbiol Infect Dis*. 2005;52(2):123–127. doi:10.1016/j.diagmicrobio.2005.02.011

38. Tulkens PM. Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin. *J Antimicrob Chemother.* 1991;27(SUPPL. C):49–61.
doi:10.1093/jac/27.suppl_c.49
39. Thomson AH, Way S, Bryson SM, McGovern EM, Kelman AW WB. Population pharmacokinetics of gentamicin in neonates. *Dev Pharmacol Ther.* 1988;11(3):173–179. doi:doi:10.1159/000457685
40. Falcão AC, Buelga DS, Méndez ME, García MJ, Pardo M. Population kinetics of tobramycin in neonates. *Ther Drug Monit.* 2001;23(3):202–208.
doi:10.1097/00007691-200106000-00004
41. Langhendries JP, Battisti O, Bertrand JM, et al. Adaptation in neonatology of the once-daily concept of aminoglycoside administration: Evaluation of a dosing chart for amikacin in an intensive care unit. *Biol Neonate.* 1998;74(5):351–362. doi:10.1159/000014053
42. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa D v., Ioannidis JPA. Extended-interval aminoglycoside administration for children: a meta-analysis. *Pediatrics.* 2004;114(1):111–118. doi:10.1542/peds.114.1.e111
43. Hartman SJF, Brüggemann RJ, Orriëns L, Dia N, Schreuder MF, de Wildt SN. Pharmacokinetics and target attainment of antibiotics in critically ill children: A systematic review of current literature. *Clin Pharmacokinet.* 2020;59(2):173–205. doi:10.1007/s40262-019-00813-w

44. Sum BL, Veltkamp SA, Westerman EM, Sprij AJ, Touw DJ. An extended-interval gentamicin dosage regimen in newborns : a prospective study. *Eur J Hosp Pharm.* 2007;13(4):98–104.
45. Lulic-Botica M, Sheer T, Edwards D, Thomas RL, Natarajan G. Impact of small-for-gestational age (sga) status on gentamicin pharmacokinetics in neonates. *J Clin Pharmacol.* 2014;54(1):39–45. doi:10.1002/jcph.190
46. Rybak MJ, Le J, Lodise TP, et al. Executive summary: Therapeutic monitoring of vancomycin for serious methicillin-resistant *Staphylococcus aureus* infections: A revised consensus guideline and review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *Pharmacotherapy.* 2020;40(4):363–367. doi:10.1002/phar.2376
47. Tang Z, Guan J, Li J, et al. Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing. *Int J Antimicrob Agents.* 2021;57(3):106300. doi:10.1016/j.ijantimicag.2021.106300
48. Lee SM, Yang S, Kang S, Chang MJ. Population pharmacokinetics and dose optimization of vancomycin in neonates. *Sci Rep.* 2021;11(1):1–8. doi:10.1038/s41598-021-85529-3
49. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: We can't get there from here. *Clin Infect Dis.* 2011;52(8):969–974. doi:10.1093/cid/cir078

50. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. *Clin Infect Dis*. 2009;49(4):507–514. doi:10.1086/600884
51. Abdul-Aziz MH, Lipman J, Akova M, et al. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. *J Antimicrob Chemother*. 2016;71(1):196–207. doi:10.1093/jac/dkv288
52. Roberts JA, Boots R, Rickard CM, et al. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. *J Antimicrob Chemother*. 2007;59(2):285–291. doi:10.1093/jac/dkl478
53. Maarseveen EM van, Man WH, Touw DJ. Continue en intermitterende infusie van vancomycine even effectief. *Nederlands Tijdschrift voor Geneeskunde*. 2011;155(42):A2667.
54. Han J, Sauberan J, Tran MT, et al. Implementation of vancomycin therapeutic monitoring guidelines: Focus on Bayesian estimation tools in neonatal and pediatric patients. *Ther Drug Monit*. Published online 2021. doi:10.1097/FTD.0000000000000910
55. Sime FB, Udy AA, Roberts JA. Augmented renal clearance in critically ill patients: Etiology, definition and implications for beta-lactam dose

- optimization. *Curr Opin Pharmacol.* 2015;24:1--6.
doi:10.1016/j.coph.2015.06.002
56. Abdulla A, Ewoldt TMJ, Hunfeld NGM, et al. The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: The DOLPHIN trial protocol of a multi-centre randomised controlled trial. *BMC Infect Dis.* 2020;20(1):1–9.
doi:10.1186/s12879-020-4781-x
57. Raposo J, Teotónio R, Bento C, Sales F. Amoxicillin, a potential epileptogenic drug. *Epileptic Disord.* 2016;18(4):454–457. doi:10.1684/epd.2016.0875
58. Schliamser SE, Cars O, Norrby SR. Neurotoxicity of β -lactam antibiotics: Predisposing factors and pathogenesis. *J Antimicrob Chemother.* 1991;27(4):405–425. doi:10.1093/jac/27.4.405
59. Wu YE, Wang T, Yang HL, et al. Population pharmacokinetics and dosing optimization of azlocillin in neonates with early-onset sepsis: a real-world study. *J Antimicrob Chemother* 2021;76(3):699–709. doi:10.1093/jac/dkaa468
60. Du B, Zhou Y, Tang B-H, et al. Population pharmacokinetic study of cefathiamidine in infants with augmented renal clearance. *Front Pharmacol.* 2021;12(March):1–8. doi:10.3389/fphar.2021.630047
61. van Donge T, Fuchs A, Leroux S, et al. Amoxicillin dosing regimens for the treatment of neonatal sepsis: Balancing efficacy and neurotoxicity. *Neonatology.* 2021;117(5):619–627. doi:10.1159/000509751

62. Frankenbusch K, Eifinger F, Kribs A, Rengelshauseu J, Roth B. Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight. *J Perinatol.* 2006;26(8):511–514. doi:10.1038/sj.jp.7211532
63. Turan Ö, Ergenekon E, Murat Hirfanogălu I, et al. Combination antifungal therapy with voriconazole for persistent candidemia in very low birth weight neonates. *Turk J Pediatr.* 2011;53(1):19–26.
64. Li Z, Chen Y, Li Q, et al. Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants. *Eur J Clin Pharmacol.* 2013;69(6):1223–1233. doi:10.1007/s00228-012-1413-4
65. Cohen-Wolkowicz M, Benjamin DK, Ross A, et al. Population pharmacokinetics of piperacillin using scavenged samples from preterm infants. *Ther Drug Monit.* 2012;34(3):312–319. doi:10.1097/FTD.0b013e3182587665
66. Germovsek E, Lutsar I, Kipper K, et al. Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: Results from the NeoMero studies. *J Antimicrob Chemother.* 2018;73(7):1908–1916. doi:10.1093/jac/dky128
67. van Enk JG, Touw DJ, Lafeber HN. Pharmacokinetics of meropenem in preterm neonates. *Ther Drug Monit.* 2001;23(3):198–201.
68. Ohata Y, Tomita Y, Nakayama M, Kozuki T, Sunakawa K, Tanigawara Y. Optimal dosage regimen of meropenem for pediatric patients based on

- pharmacokinetic/pharmacodynamic considerations. *Drug Metab Pharmacokinet.* 2011;26(5):523–531. doi:10.2133/dmpk.DMPK-11-RG-027
69. van den Anker JN, Pokorna P, Kinzig-Schippers M, et al. Meropenem pharmacokinetics in the newborn. *Antimicrob Agents Chemother.* 2009;53(9):3871–3879. doi:10.1128/AAC.00351-09
70. Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. *J Clin Pharmacol.* 2006;46:1171–1178. doi:10.1177/0091270006291035
71. Wahab mohamed WA, Ismail M. A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants. *J Trop Pediatr.* 2012;58(1):25–30. doi:10.1093/tropej/fmr025
72. Kadam RS, van den Anker JN. Pediatric clinical pharmacology of voriconazole: Role of pharmacokinetic/pharmacodynamic modeling in pharmacotherapy. *Clin Pharmacokinet.* 2016;55:1031–1043. doi:10.1007/s40262-016-0379-2
73. Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. *Clin Infect Dis.* 2010;50(1):27–36. doi:10.1086/648679
74. Kim SH, Yim DS, Choi SM, et al. Voriconazole-related severe adverse events: Clinical application of therapeutic drug monitoring in Korean patients. *Int J Infect Dis.* 2011;15(11):e753–e758. doi:10.1016/j.ijid.2011.06.004

75. ter Avest M, Veringa A, van den Heuvel ER, et al. The effect of inflammation on voriconazole trough concentrations in children. *Br J Clin Pharmacol*. 2017;83(3):678–680. doi:10.1111/bcp.13151
76. Lempers VJ, Meuwese E, Mavinkurve-Groothuis AM, et al. Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients. *Med Mycol*. 2019;57(8):937–943. doi:10.1093/mmy/myz006
77. Abo YN, Gwee A, Osowicki J. Rare infant case of pulmonary aspergilloma highlighting common challenges with voriconazole dosing. *Pediatr Infect Dis J*. 2021;40(3):227–230. doi:10.1097/INF.0000000000002959
78. Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. *Antimicrob Agents Chemother*. 2007;51(1):35–39. doi:10.1128/AAC.00474-06
79. Clancy CJ, Yu VL, Morris AJ, Snyderman DR, Nguyen MH. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. *Antimicrob Agents Chemother*. 2005;49(8):3171–3177. doi:10.1128/AAC.49.8.3171-3177.2005
80. Hornik CD, Bondi DS, Greene NM, Cober MP, John B. Review of fluconazole treatment and prophylaxis for invasive candidiasis in neonates. *J Pediatr Pharmacol Ther*. 2021;26(2):115–122. doi:10.5863/1551-6776-26.2.115

81. Egunsola O, Adefurin A, Fakis A, Jacqz-Aigrain E, Choonara I, Sammons H. Safety of fluconazole in paediatrics: A systematic review. *Eur J Clin Pharmacol.* 2013;69(6):1211–1221. doi:10.1007/s00228-012-1468-2
82. Matsumoto K, Ueno K, Yoshimura H, et al. Fluconazole-induced convulsions at serum trough concentrations of approximately 80 microg/mL. *Ther Drug Monit.* 2000;22(5):635–636. doi:10.1097/00007691-200010000-00022

ACCEPTED

Tables

Table 1: Overview of national Dutch dose recommendations for gentamicin in preterm and in term neonates depending on gestational age (GA) and postnatal age (PNA).

Patient characteristic	Dose (mg/kg)	Dose interval (h)
Preterm <32 weeks GA, <7 d PNA	5	48
Preterm 32-37 weeks GA, <7 d PNA	5	36
Preterm, >7 d PNA	4	24
Term, <7 d PNA	4	24
Term, >7 d PNA	4	24
1 month–18 years	7	24

Table 2: Overview of national Dutch dose recommendations for vancomycin in preterm and term neonates.


Characteristic	Dose (mg/kg)	Dose interval (h)
Preterm, <7 d PNA	10	12
Preterm, >7 d PNA	10	12
Term, <7 d PNA	8	6
Term, >7 d PNA	12	6
1 month–18 years	15	6


Figures

Figure 1. Upper panel: Change in the volume of distribution (V_d) causes the greatest change in the concentration data point S when the latter is at its highest value (true peak concentration). This is the optimal time to calculate V_d for a one-compartment model with intermittent intravenous administration.

Lower panel: A change in the elimination rate (k_{el}) causes the greatest change in concentration data point S , which is 1.44 half-lives after the end of intravenous administration. This is the optimal time to calculate the k_{el} for a 1-compartment model with intermittent intravenous administration.

Adapted with permission from Jelliffe et al. *Clin Pharmacokinet.* 1991;21(6):461–478.





ACCEPTED

Figure 2. Horizontal axis represents time of exposure to a certain concentration of the antibiotic. The vertical axis represents the number of colony-forming units (CFU).

*When a microorganism, such as *Pseudomonas aeruginosa*, is exposed to an increasing concentration of tobramycin, its killing action (expressed as a decrease in CFU versus time) increases exponentially.*

Adapted with permission from Craig et al. Scand J Infect Dis Suppl. 1990;74:63–70.

www.tandfonline.com.

ACCEPTED

Tobramycin







Figure 3: Percentage of neonates within different ranges of peak steady-state concentrations (C_{peak}) of gentamicin in the subpopulations GA <35 weeks ($N = 64$) and GA \geq 35 weeks ($N = 51$).


Modified with permission from Sum et al. *Eur J Hosp Pharm.* 2007;13(4):98–104.








Tobramycin





Slide 1

A1

I have examined this figure, and have no suggested edits.

Author, 05-07-2021

ACCEPTED